{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:49:15Z","timestamp":1781570955166,"version":"3.54.5"},"reference-count":66,"publisher":"Portland Press Ltd.","issue":"1","license":[{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"vor","delay-in-days":198,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Angiotensinogen (AGT) is the unique substrate of all angiotensin peptides. We review the recent preclinical research of AGT antisense oligonucleotides (ASOs), a rapidly evolving therapeutic approach. The scope of the research findings not only opens doors for potentially new therapeutics of hypertension and many other diseases, but also provides insights into understanding critical physiological and pathophysiological roles mediated by AGT.<\/jats:p>","DOI":"10.1042\/bsr20180201","type":"journal-article","created":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T16:49:16Z","timestamp":1544460556000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Antisense oligonucleotides targeting angiotensinogen: insights from animal studies"],"prefix":"10.1042","volume":"39","author":[{"given":"Chia-Hua","family":"Wu","sequence":"first","affiliation":[{"name":"Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, U.S.A."},{"name":"Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Wang","sequence":"additional","affiliation":[{"name":"Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, U.S.A."},{"name":"The Second Affiliated Hospital, Cardiovascular Key Laboratory of Zhejiang Province, Department of Cardiology, College of Medicine, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murong","family":"Ma","sequence":"additional","affiliation":[{"name":"Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, U.S.A."},{"name":"Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam\u00a0E.","family":"Mullick","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Carlsbad, CA, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne\u00a0M.","family":"Crooke","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Carlsbad, CA, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00a0J.","family":"Graham","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc., Carlsbad, CA, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Daugherty","sequence":"additional","affiliation":[{"name":"Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, U.S.A."},{"name":"Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, U.S.A."},{"name":"Department of Physiology, University of Kentucky, Lexington, KY, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong\u00a0S.","family":"Lu","sequence":"additional","affiliation":[{"name":"Saha Cardiovascular Research Center, University of Kentucky, Lexington, KY, U.S.A."},{"name":"Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, U.S.A."},{"name":"Department of Physiology, University of Kentucky, Lexington, KY, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"2021111617015143000_B1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"2021111617015143000_B2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2021111617015143000_B3","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nature06796","article-title":"Translating molecular discoveries into new therapies for atherosclerosis","volume":"451","author":"Rader","year":"2008","journal-title":"Nature"},{"key":"2021111617015143000_B4","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1161\/ATVBAHA.118.311282","article-title":"Renin-angiotensin system and cardiovascular functions","volume":"38","author":"Wu","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021111617015143000_B5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.phrs.2017.05.020","article-title":"Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease","volume":"125","author":"Ferrario","year":"2017","journal-title":"Pharmacol. Res."},{"key":"2021111617015143000_B6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.7156\/v4i4p183","article-title":"Molecular and pathophysiological features of angiotensinogen: a mini review","volume":"4","author":"Wu","year":"2011","journal-title":"N. Am. J. Med. Sci. (Boston)"},{"key":"2021111617015143000_B7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/hr.2016.17","article-title":"Structure and functions of angiotensinogen","volume":"39","author":"Lu","year":"2016","journal-title":"Hypertens. Res."},{"key":"2021111617015143000_B8","doi-asserted-by":"crossref","first-page":"31334","DOI":"10.1016\/S0021-9258(18)31697-1","article-title":"Angiotensinogen-deficient mice with hypotension","author":"Tanimoto","year":"1994","journal-title":"J. Biol. Chem."},{"key":"2021111617015143000_B9","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1073\/pnas.91.9.3612","article-title":"Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice","volume":"91","author":"Smithies","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111617015143000_B10","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1161\/HYPERTENSIONAHA.115.05166","article-title":"Cys18-Cys137 disulfide bond in mouse angiotensinogen does not affect AngII-dependent functions in vivo","volume":"65","author":"Wu","year":"2015","journal-title":"Hypertension"},{"key":"2021111617015143000_B11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1161\/ATVBAHA.115.306740","article-title":"Angiotensinogen exerts effects independent of angiotensin II","volume":"36","author":"Lu","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021111617015143000_B12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1681\/ASN.2011121159","article-title":"Liver angiotensinogen is the primary source of renal angiotensin II","volume":"23","author":"Matsusaka","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111617015143000_B13","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"key":"2021111617015143000_B14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/nass\/nrn280","article-title":"Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs","author":"Seth","year":"2008","journal-title":"Nucleic Acids Symp. Ser. (Oxf.)"},{"key":"2021111617015143000_B15","first-page":"347","article-title":"Antisense oligonucleotides: basic concepts and mechanisms","volume":"1","author":"Dias","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"2021111617015143000_B16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11906-005-0088-y","article-title":"Molecular evidence of tissue renin-angiotensin systems: a focus on the brain","volume":"7","author":"Sakai","year":"2005","journal-title":"Curr. Hypertens. Rep."},{"key":"2021111617015143000_B17","doi-asserted-by":"publisher","first-page":"R238","DOI":"10.1152\/ajpregu.00486.2014","article-title":"Mechanisms of brain renin angiotensin system-induced drinking and blood pressure: importance of the subfornical organ","volume":"308","author":"Coble","year":"2015","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2021111617015143000_B18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0167-0115(93)90438-E","article-title":"Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin","volume":"49","author":"Gyurko","year":"1993","journal-title":"Regul. Pept."},{"key":"2021111617015143000_B19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1253\/jcj.27.282","article-title":"Development of a strain of spontaneously hypertensive rats","volume":"27","author":"Okamoto","year":"1963","journal-title":"Jpn. Circ. J."},{"key":"2021111617015143000_B20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1161\/01.HYP.25.3.314","article-title":"Antisense inhibition of hypertension in the spontaneously hypertensive rat","volume":"25","author":"Wielbo","year":"1995","journal-title":"Hypertension"},{"key":"2021111617015143000_B21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1161\/01.HYP.31.6.1317","article-title":"Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood","volume":"31","author":"Peng","year":"1998","journal-title":"Hypertension"},{"key":"2021111617015143000_B22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1161\/01.HYP.37.2.371","article-title":"Antisense inhibition of brain renin-angiotensin system decreased blood pressure in chronic 2-kidney, 1 clip hypertensive rats","volume":"37","author":"Kagiyama","year":"2001","journal-title":"Hypertension"},{"key":"2021111617015143000_B23","first-page":"F1068","article-title":"Role of paraventricular nucleus in control of blood pressure and drinking in rats","volume":"262","author":"Jensen","year":"1992","journal-title":"Am. J. Physiol."},{"key":"2021111617015143000_B24","first-page":"R302","article-title":"Subfornical organ efferents to paraventricular nucleus utilize angiotensin as a neurotransmitter","volume":"265","author":"Li","year":"1993","journal-title":"Am. J. Physiol."},{"key":"2021111617015143000_B25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S0006-8993(99)01375-X","article-title":"Antisense inhibition of angiotensinogen attenuates vasopressin release in the paraventricular hypothalamic nucleus of spontaneously hypertensive rats","volume":"829","author":"Kagiyama","year":"1999","journal-title":"Brain Res."},{"key":"2021111617015143000_B26","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/0024-3205(91)90480-Y","article-title":"Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera","volume":"49","author":"Akhtar","year":"1991","journal-title":"Life Sci."},{"key":"2021111617015143000_B27","doi-asserted-by":"publisher","first-page":"7595","DOI":"10.1073\/pnas.88.17.7595","article-title":"Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice","volume":"88","author":"Agrawal","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111617015143000_B28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1096\/fasebj.7.6.7682523","article-title":"Progress toward oligonucleotide therapeutics: pharmacodynamic properties","volume":"7","author":"Crooke","year":"1993","journal-title":"FASEB J."},{"key":"2021111617015143000_B29","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.118.311817","article-title":"Angiotensinogen and megalin interactions contribute to atherosclerosis","volume":"39","author":"Ye","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021111617015143000_B30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cmet.2011.03.001","article-title":"AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure","volume":"13","author":"Gurley","year":"2011","journal-title":"Cell Metab."},{"key":"2021111617015143000_B31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/01.HYP.26.1.131","article-title":"Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen","volume":"26","author":"Tomita","year":"1995","journal-title":"Hypertension"},{"key":"2021111617015143000_B32","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1097\/00004872-199512010-00048","article-title":"Effect of angiotensinogen on blood pressure regulation in normotensive rats: application of a loss of function approach","volume":"13","author":"Tomita","year":"1995","journal-title":"J. Hypertens."},{"key":"2021111617015143000_B33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/01.HYP.27.3.502","article-title":"Role of transcriptional cis-elements, angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation","volume":"27","author":"Morishita","year":"1996","journal-title":"Hypertension"},{"key":"2021111617015143000_B34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/01.HYP.28.1.147","article-title":"Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides","volume":"28","author":"Wielbo","year":"1996","journal-title":"Hypertension"},{"key":"2021111617015143000_B35","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1161\/01.HYP.37.2.376","article-title":"Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense","volume":"37","author":"Kimura","year":"2001","journal-title":"Hypertension"},{"key":"2021111617015143000_B36","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1161\/01.HYP.31.5.1166","article-title":"Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats","volume":"31","author":"Makino","year":"1998","journal-title":"Hypertension"},{"key":"2021111617015143000_B37","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"2021111617015143000_B38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1753944716642680","article-title":"Drug discovery in renin-angiotensin system intervention: past and future","volume":"10","author":"Williams","year":"2016","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"2021111617015143000_B39","first-page":"984","article-title":"Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice","volume":"118","author":"Lu","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2021111617015143000_B40","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.117.09755","article-title":"Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury","volume":"70","author":"Mullick","year":"2017","journal-title":"Hypertension"},{"key":"2021111617015143000_B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000320387","article-title":"High-salt diet and hypertension: focus on the renin-angiotensin system","volume-title":"Kidney Blood Press Res.","author":"Drenjancevic-Peric","year":"2011"},{"key":"2021111617015143000_B42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1440-1681.1990.tb01312.x","article-title":"High salt diet ameliorates effects of angiotensin converting enzyme inhibition in spontaneously hypertensive streptozotocin diabetic rats","volume":"17","author":"Jackson","year":"1990","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"2021111617015143000_B43","doi-asserted-by":"publisher","first-page":"H853","DOI":"10.1152\/ajpheart.00737.2007","article-title":"AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure","volume":"294","author":"Varagic","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021111617015143000_B44","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2174\/138161207780618867","article-title":"Attenuation of bleomycin-induced pulmonary fibrosis by intratracheal administration of antisense oligonucleotides against angiotensinogen mRNA","volume":"13","author":"Li","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"2021111617015143000_B45","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/1753944716642677","article-title":"Cardiac remodelling and RAS inhibition","volume":"10","author":"Ferrario","year":"2016","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"2021111617015143000_B46","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCRESAHA.109.212837","article-title":"Angiotensin II induces a region-specific hyperplasia of the ascending aorta through regulation of inhibitor of differentiation 3","volume":"106","author":"Owens","year":"2010","journal-title":"Circ. Res."},{"key":"2021111617015143000_B47","doi-asserted-by":"publisher","first-page":"e48462","DOI":"10.1371\/journal.pone.0048462","article-title":"Regional variation in aortic AT1b receptor mRNA abundance is associated with contractility but unrelated to atherosclerosis and aortic aneurysms","volume":"7","author":"Poduri","year":"2012","journal-title":"PLoS ONE"},{"key":"2021111617015143000_B48","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0008-6363(99)00254-0","article-title":"Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats","volume":"44","author":"Makino","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"2021111617015143000_B49","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/00004872-200018060-00010","article-title":"Reduction of plasma angiotensin II to normal levels by antisense oligodeoxynucleotides against liver angiotensinogen cannot completely attenuate vascular remodeling in spontaneously hypertensive rats","volume":"18","author":"Sugano","year":"2000","journal-title":"J. Hypertens."},{"key":"2021111617015143000_B50","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1161\/01.CIR.0000150540.54220.C4","article-title":"Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor","volume":"110","author":"Daugherty","year":"2004","journal-title":"Circulation"},{"key":"2021111617015143000_B51","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1161\/01.RES.0000115557.25127.8D","article-title":"Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor","volume":"94","author":"Wassmann","year":"2004","journal-title":"Circ. Res."},{"key":"2021111617015143000_B52","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1161\/01.ATV.0000254680.71485.92","article-title":"Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms","volume":"27","author":"Cassis","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021111617015143000_B53","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1291\/hypres.31.1631","article-title":"The long-term effect of angiotensin II type 1a receptor deficiency on hypercholesterolemia-induced atherosclerosis","volume":"31","author":"Eto","year":"2008","journal-title":"Hypertens. Res."},{"key":"2021111617015143000_B54","doi-asserted-by":"publisher","first-page":"e51483","DOI":"10.1371\/journal.pone.0051483","article-title":"Depletion of endothelial or smooth muscle cell-specific angiotensin II type 1a receptors does not influence aortic aneurysms or atherosclerosis in LDL receptor deficient mice","volume":"7","author":"Rateri","year":"2012","journal-title":"PLoS ONE"},{"key":"2021111617015143000_B55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fped.2017.00221","article-title":"Genetics of autosomal recessive polycystic kidney disease and its differential diagnoses","volume":"5","author":"Bergmann","year":"2017","journal-title":"Front. Pediatr."},{"key":"2021111617015143000_B56","doi-asserted-by":"publisher","first-page":"F775","DOI":"10.1152\/ajprenal.00370.2003","article-title":"The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease","volume":"287","author":"Loghman-Adham","year":"2004","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021111617015143000_B57","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJM199010183231602","article-title":"The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease","volume":"323","author":"Chapman","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"2021111617015143000_B58","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12405","article-title":"Activation of the intrarenal renin-angiotensin-system in murine polycystic kidney disease","volume":"3","author":"Saigusa","year":"2015","journal-title":"Physiol. Rep."},{"key":"2021111617015143000_B59","doi-asserted-by":"publisher","first-page":"F349","DOI":"10.1152\/ajprenal.00478.2014","article-title":"Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2","volume":"308","author":"Ravichandran","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021111617015143000_B60","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1096\/fj.15-279299","article-title":"Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model","volume":"30","author":"Saigusa","year":"2016","journal-title":"FASEB J."},{"key":"2021111617015143000_B61","doi-asserted-by":"publisher","first-page":"F210","DOI":"10.1152\/ajprenal.00389.2017","article-title":"Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade","volume":"314","author":"Fitzgibbon","year":"2018","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021111617015143000_B62","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1161\/ATVBAHA.117.309524","article-title":"Consideration of sex differences in design and reporting of experimental arterial pathology studies-Statement From ATVB Council","volume":"38","author":"Robinet","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021111617015143000_B63","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1161\/ATVBAHA.116.307301","article-title":"Sex hormones and sex chromosomes cause sex differences in the development of cardiovascular diseases","volume":"37","author":"Arnold","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021111617015143000_B64","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/ki.1994.446","article-title":"Angiotensinogen: hormonal regulation and relative importance in the generation of angiotensin II","volume":"46","author":"Deschepper","year":"1994","journal-title":"Kidney Int."},{"key":"2021111617015143000_B65","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111617015143000_B66","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1038\/ki.1994.444","article-title":"Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes","volume":"46","author":"Phillips","year":"1994","journal-title":"Kidney Int."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20180201\/844267\/bsr-2018-0201c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20180201\/844267\/bsr-2018-0201c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T17:07:31Z","timestamp":1637082451000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/39\/1\/BSR20180201\/183\/Antisense-oligonucleotides-targeting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20180201","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2019,1]]},"article-number":"BSR20180201"}}